Examinando por Autor "Astorga, Constanza"

Mostrando 1 - 3 de 3
  • No hay miniatura disponible
    Ítem
    Clinical Characteristics of Neuropathic Pain and Its Relationship with Cancer in Different Corporal Areas—A Systematic Review
    (Multidisciplinary Digital Publishing Institute (MDPI), 0025-01) Danés-López, Fernanda; Diaz-Palominos, Cristóbal; Ortiz Domínguez, Anggie; Silva Rodriguez, Alanna; Astorga, Constanza; Martínez-Hernández, Daniela; Valenzuela-Fuenzalida, Juan Jose; Sanchis-Gimeno, Juan; Nova-Baeza, Pablo; Suazo-Santibáñez, Alejandra; Oyanedel-Amaro, Gustavo; Orellana-Donoso, Mathias
    Background: Neuropathic pain (NP) and cancer are caused by nerve damage due to cancer or treatments such as chemotherapy, radiotherapy, and surgery, with a prevalence that can reach up to 40%. Causes of neuropathic cancer pain (NCP) include direct nerve invasion or compression by the tumor, as well as neural toxicity associated with treatments. This type of pain is classified into several categories, such as plexopathy, radiculopathy, and peripheral neuropathies. Methods: Medline, Web of Science, Google Scholar, CINAHL, and LILACS databases were searched until October 2024. Two authors independently performed the search, study selection, and data extraction. Methodological quality was analyzed using the Robins-I tool. Results: The main findings of this review indicate that, depending on the cancer type, neuropathic pain will exhibit different characteristics, as well as identifying which types of cancer have a higher probability of presenting neuropathic pain. Additionally, there is a direct relationship whereby the more advanced the cancer, the greater the likelihood of experiencing neuropathic pain. Finally, although chemotherapy is employed as a cancer treatment, this therapy is quite invasive, and one of its adverse effects is that treated patients have a higher probability of developing neuropathic pain. Conclusions: Neuropathic pain is a condition that adversely affects patients with cancer. A detailed understanding of the relationships and triggers that produce this condition is present in only a small percentage of patients with cancer and is necessary to provide better treatment and gain a more comprehensive understanding of the characteristics of neuropathic pain. The objective of this study is to describe the relationship between different types of cancer or various treatments and the presence of NP. © 2025 by the authors.
  • No hay miniatura disponible
    Ítem
    Clinical Characteristics of Neuropathic Pain and Its Relationship with Cancer in Different Corporal Areas—A Systematic Review
    (Multidisciplinary Digital Publishing Institute (MDPI), 0025-01) Danés-López, Fernanda; Diaz-Palominos, Cristóbal; Ortiz Domínguez, Anggie; Silva Rodriguez, Alanna; Astorga, Constanza; Martínez-Hernández, Daniela; Valenzuela-Fuenzalida, Juan Jose; Sanchis-Gimeno, Juan; Nova-Baeza, Pablo; Suazo-Santibáñez, Alejandra; Oyanedel-Amaro, Gustavo; Orellana-Donoso, Mathias
    Background: Neuropathic pain (NP) and cancer are caused by nerve damage due to cancer or treatments such as chemotherapy, radiotherapy, and surgery, with a prevalence that can reach up to 40%. Causes of neuropathic cancer pain (NCP) include direct nerve invasion or compression by the tumor, as well as neural toxicity associated with treatments. This type of pain is classified into several categories, such as plexopathy, radiculopathy, and peripheral neuropathies. Methods: Medline, Web of Science, Google Scholar, CINAHL, and LILACS databases were searched until October 2024. Two authors independently performed the search, study selection, and data extraction. Methodological quality was analyzed using the Robins-I tool. Results: The main findings of this review indicate that, depending on the cancer type, neuropathic pain will exhibit different characteristics, as well as identifying which types of cancer have a higher probability of presenting neuropathic pain. Additionally, there is a direct relationship whereby the more advanced the cancer, the greater the likelihood of experiencing neuropathic pain. Finally, although chemotherapy is employed as a cancer treatment, this therapy is quite invasive, and one of its adverse effects is that treated patients have a higher probability of developing neuropathic pain. Conclusions: Neuropathic pain is a condition that adversely affects patients with cancer. A detailed understanding of the relationships and triggers that produce this condition is present in only a small percentage of patients with cancer and is necessary to provide better treatment and gain a more comprehensive understanding of the characteristics of neuropathic pain. The objective of this study is to describe the relationship between different types of cancer or various treatments and the presence of NP. © 2025 by the authors.
  • No hay miniatura disponible
    Ítem
    Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
    (Elsevier B.V., 2023-05) Méndez, Constanza; Peñaloza, Hernán F.; Schultz, Bárbara M.; Piña-Iturbe, Alejandro; Ríos, Mariana; Moreno-Tapia, Daniela; Pereira-Sánchez, Patricia; Leighton, Diane; Orellana, Claudia; Covarrubias, Consuelo; Gálvez, Nicolás M.S.; Soto, Jorge A.; Duarte, Luisa F.; Rivera-Pérez, Daniela; Vázquez, Yaneisi; Cabrera, Alex; Bustos, Sergio; Iturriaga, Carolina; Urzua, Marcela; Navarrete, María S.; Rojas, Álvaro; Fasce, Rodrigo A.; Fernández, Jorge; Mora, Judith; Ramírez, Eugenio; Gaete-Argel, Aracelly; Acevedo, Mónica; Valiente-Echeverría, Fernando; Soto-Rifo, Ricardo; Weiskopf, Daniela; Grifoni, Alba; Sette, Alessandro; Zeng, Gang; Meng, Weining; Del Río, Constanza; Del Pino, Dinely; Aguirre, Natalia; Salinas, Grecia; Vega, Franco; Salgado, Acsa; Quinteros, Thomas; Ortiz, Marlene; Puente, Marcela; Muñoz, Alma; Astudillo, Patricio; Le Corre, Nicole; Potin, Marcela; Catalán, Juan; Peralta, Melan; Zamanillo, Consuelo; Keller, Nicole; Fernández, Rocío; Aljaro, Sofía; López, Sofía; González, José Tomás; Weil, Tania; Opazo, Luz; Muñoz, Paula; Estay, Inés; Cantillana, Miguel; Carrera, Liliana; Masalleras, Matías; Guzmán, Paula; Aguirre, Francisca; Cortés, Aarón; Bátiz, Luis Federico; Pérez, Javiera; Apablaza, Karen; Yates, Lorena; Valdés, María de los Ángeles; Hurtado, Bernardita; Venteneul, Veronique; Astorga, Constanza; Muñoz-Venturelli, Paula; Vial, Pablo A.; Schilling, Andrea; Pavez, Daniela; Pérez, Inia; Riviotta, Amy; González, Francisca; Urrutia, Francisca; Del Río, Alejandra; Asenjo, Claudia; Vargas, Bárbara; Castro, Francisca; Acuña, Alejandra; Guzmán, Javiera; Astudillo, Camila; Pérez, Carlos M.; Espinoza, Pilar; Martínez, Andrea; Arancibia, Marcela; Romero, Harold; Bustamante, Cecilia; Pérez, María Loreto; Uribe, Natalia; Silva, Viviana; Morice, Bernardita; Pérez, Marco; González, Marcela; Jensen, Werner; Pasten, Claudia; Aguilera, M. Fernanda; Martínez, Nataly; Molina, Camila; Arrieta, Sebastián; López, Begoña; Ortiz, Claudia; Escobar, Macarena; Bustamante, Camila; Espinoza, Marcia; Pardo, Angela; Carrasco, Alison; Montes, Miguel; Saldías, Macarena; Gutiérrez, Natalia; Sánchez, Juliette; Fuentes, Daniela; Calvo, Yolanda; Cepeda, Mariela; Lemus, Rosario; Suárez, Muriel; Armijo, Mercedes; Monsalves, Shirley; Marucich, Constance; Cornejo, Cecilia; Acosta, Ángela; Prado, Xaviera; Yáñez, Francisca; Barroeta, Marisol; López, Claudia; Donato, Paulina; Lasso, Martin; Iturrieta, María; Giraldo, Juan; Gutiérrez, Francisco; Acuña, María; Cascone, Ada; Rojas, Raymundo; Sepúlveda, Camila; Contreras, Mario; Campisto, Yessica; González, Pablo A.; Quizhpi, Zoila; López, Mariella; Pizzeghello, Vania; Silva, Stephannie; González-Aramundiz, José V.; Abarca, Katia; Melo-González, Felipe; Bueno, Susan M.; Kalergis, Alexis M.
    Background: The Omicron variant has challenged the control of the COVID-19 pandemic due to its immuno-evasive properties. The administration of a booster dose of a SARS-CoV-2 vaccine showed positive effects in the immunogenicity against SARS-CoV-2, effect that is even enhanced after the administration of a second booster. Methods: During a phase-3 clinical trial, we evaluated the effect of a second booster of CoronaVac®, an inactivated vaccine administered 6 months after the first booster, in the neutralization of SARS-CoV-2 (n = 87). In parallel, cellular immunity (n = 45) was analyzed in stimulated peripheral mononuclear cells by flow cytometry and ELISPOT. Findings: Although a 2.5-fold increase in neutralization of the ancestral SARS-CoV-2 was observed after the second booster when compared with prior its administration (Geometric mean units p < 0.0001; Geometric mean titer p = 0.0002), a poor neutralization against the Omicron variant was detected. Additionally, the activation of specific CD4+ T lymphocytes remained stable after the second booster and, importantly, equivalent activation of CD4+ T lymphocytes against the Omicron variant and the ancestral SARS-CoV-2 were found. Interpretation: Although the neutralizing response against the Omicron variant after the second booster of CoronaVac® was slightly increased, these levels are far from those observed against the ancestral SARS-CoV-2 and could most likely fail to neutralize the virus. In contrast, a robust CD4+T cell response may confer protection against the Omicron variant. Funding: The Ministry of Health, Government of Chile, the Confederation of Production and Commerce, Chile and SINOVAC Biotech. NIH NIAID. The Millennium Institute on Immunology and Immunotherapy. © 2023 The Author(s)